Pfizer's stock has fallen more than 50% from its 2021 high. The stock is trading below its pre-coronavirus pandemic level.
Is Pfizer Stock a "Value Trap" or a Generational Opportunity?
Source: The Motley Fool
More PFE News
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
GuruFocus·8h ago
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers
Investors Business Daily·9h ago
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Business Wire·9h ago
Mailbag: A Follow-Up on Pfizer & Other Questions
ETF Trends·1 day ago
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
GuruFocus·1 day ago